Page 47 | Certara

Publication

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers

Abstract T-cell engager (TCE) molecules activate the immune system and direct it to kill tumor…

CertaraSeptember 18, 2024

Publication

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

Abstract Incorporating an early evaluation of dosing requirements is crucial for assessing the viability of…

CertaraSeptember 18, 2024

On-Demand Webinar

ON DEMAND [ISoP Webinar] – Physiologically Based Pharmacokinetic (PBPK) Applications in Model Informed Drug Development (MIDD) – Do You Know the Current Landscape of Regulatory Acceptance?

Model Informed Drug Development (MIDD) is a critical component in the drug development process and…

CertaraSeptember 16, 2024

Guide

A Best Practice Guide to Managing Non-CRF Data

CertaraSeptember 16, 2024

Case Study

Inferring Target Occupancy for Pembrolizumab

Pembrolizumab (Pembro), an anti-PD-1 antibody, has been approved for several cancer indications at 200 mg…

CertaraSeptember 16, 2024

Poster

Dynamic Target-Mediated Drug Disposition (TMDD)

Abstract Methods: We have developed a novel pharmacokinetic model, termed dynamic TMDD, to mechanistically describe the…

CertaraSeptember 16, 2024

Poster

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Abstract Trimer formation is key to the pharmacology of the bispecific ATG-101 but is difficult…

CertaraSeptember 16, 2024

Poster

Blinatumomab Trimer Formation

Insights from a Mechanistic PKPD Model on the Implications for Switching from Infusion to Subcutaneous…

CertaraSeptember 16, 2024

On-Demand Webinar

Quantitative Systems Pharmacology (QSP) Enabled First-in-Human Study in Oncology

CertaraSeptember 16, 2024

Press Coverage

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities

Panelists: Adekemi Taylor, PhD, VP, Quantitive Science Services at CertaraJoab Williamson, Director of Clinical Operations,…

CertaraSeptember 16, 2024

A Next Generation Mathematical Model for the in vitro to Clinical Translation of T-cell Engagers

Mechanistic PK/PD modeling to address early-stage biotherapeutic dosing feasibility questions

ON DEMAND [ISoP Webinar] – Physiologically Based Pharmacokinetic (PBPK) Applications in Model Informed Drug Development (MIDD) – Do You Know the Current Landscape of Regulatory Acceptance?

A Best Practice Guide to Managing Non-CRF Data

Inferring Target Occupancy for Pembrolizumab

Dynamic Target-Mediated Drug Disposition (TMDD)

Semi-mechanistic Model of ATG-101, a PD-L1/4-1BB Bispecific Antibody, for Treatment of Solid Tumors

Blinatumomab Trimer Formation

Quantitative Systems Pharmacology (QSP) Enabled First-in-Human Study in Oncology

Industry Sense – Drug Repurposing Unlocking New Therapeutic Possibilities

Newsletter sign up

Quick links

Solutions

Contact